Advertisement

Chronic Hepatitis C Controlled with MicroRNA-Based Treatment — Physician’s First Watch

Medical News |
March 28, 2013

Chronic Hepatitis C Controlled with MicroRNA-Based Treatment

By Joe Elia

At least temporary control of hepatitis C has been achieved with use of a microRNA-based therapy, according to a New England Journal of Medicine study. (MicroRNAs are small pieces of RNA that can suppress cellular functions.)

In a phase 2 trial sponsored and partially conducted by the therapy's developer, researchers used miravirsen to block microRNA miR-122, which is native to the liver and necessary for viral replication of hepatitis C. The double-blind, placebo-controlled trial in 36 patients used varying doses of miravirsen given over 29 days.

After 18 weeks' follow-up, levels of hepatitis C RNA had fallen significantly in all treated patients, but not the controls. At the higher dosages, viral RNA levels showed maximum drops of a thousandfold and were undetectable in some individuals. Viral levels did, however, begin to rise again after treatment.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement